These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2693128)

  • 41. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 42. Erythropoietin: from mountain top to bedside.
    Erslev AJ; Caro J
    Adv Exp Med Biol; 1989; 271():1-7. PubMed ID: 2486278
    [No Abstract]   [Full Text] [Related]  

  • 43. [Factors limiting the correction of anemia with recombinant human erythropoietin].
    Casati S
    Minerva Urol Nefrol; 1991; 43(3):121-3. PubMed ID: 1817332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of anemia caused by chronic kidney failure in adults].
    Nephrol Ther; 2005 Aug; 1 Suppl 1():S1-48. PubMed ID: 16895707
    [No Abstract]   [Full Text] [Related]  

  • 45. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin.
    Gallieni M
    Int J Artif Organs; 1998 Nov; 21(11):681-6. PubMed ID: 9894741
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of erythropoietin administration in uremia.
    Gurland HJ; Samtleben W; Schmidt B
    Contrib Nephrol; 1989; 70():172-7. PubMed ID: 2670428
    [No Abstract]   [Full Text] [Related]  

  • 47. A comparison of the responses to recombinant human erythropoietin in normal and uremic subjects.
    Eschbach JW; Haley NR; Egrie JC; Adamson JW
    Kidney Int; 1992 Aug; 42(2):407-16. PubMed ID: 1405323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis-dependent chronic renal failure.
    Ohyashiki JH; Fujieda H; Ohyashiki K; Toyama K
    Am J Hematol; 1991 Jun; 37(2):141-2. PubMed ID: 2069164
    [No Abstract]   [Full Text] [Related]  

  • 49. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?
    Cruz DN; Perazella MA; Abu-Alfa AK; Mahnensmith RL
    Am J Kidney Dis; 1996 Oct; 28(4):535-40. PubMed ID: 8840943
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized, placebo-controlled clinical trial of recombinant human erythropoietin in the anemia of prematurity.
    Mentzer WC; Shannon KM; Abels RI; Freeman P; Newton N; Thompson D; Phibbs RH
    Contrib Nephrol; 1991; 88():306-12; discussion 313. PubMed ID: 2040193
    [No Abstract]   [Full Text] [Related]  

  • 51. Erythropoietin: the developing story.
    Cotes PM
    Br Med J (Clin Res Ed); 1988 Mar; 296(6625):805-6. PubMed ID: 3130919
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of recombinant human erythropoietin on interleukin-1 beta and interleukin-6 in patients on maintenance hemodialysis.
    Sayinalp N; Erdem Y; Haznedaroğlu IC; Dündar S; Cağlar S; Kirazli S
    Clin Nephrol; 1995 Dec; 44(6):404. PubMed ID: 8719556
    [No Abstract]   [Full Text] [Related]  

  • 53. Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.
    McCarthy JT; Hocum CL; Albright RC; Rogers J; Gallaher EJ; Steensma DP; Gudgell SF; Bergstralh EJ; Dillon JC; Hickson LJ; Williams AW; Dingli D
    Mayo Clin Proc; 2014 Jan; 89(1):87-94. PubMed ID: 24388026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 55. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 56. [A multicenter trial of Recormon within the framework of international controlled research].
    Tareeva IE; Nikolaev AIu; Klepikov PV; Lashutin SV; Riabov SI; Shostka GD; Ermolenko VM; Rozental' RL; Vorob'ev PA; Miagkov AV
    Ter Arkh; 1992; 64(8):59-62. PubMed ID: 1440400
    [No Abstract]   [Full Text] [Related]  

  • 57. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
    Ford PA; Mastoris J
    Transfusion; 2004 Dec; 44(12 Suppl):15S-25S. PubMed ID: 15585001
    [No Abstract]   [Full Text] [Related]  

  • 58. Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin.
    Vanrenterghem Y; Vanwalleghem J
    Nephrol Dial Transplant; 1998; 13 Suppl 2():13-5. PubMed ID: 9566485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.
    Maxwell AP
    Kidney Int; 2002 Aug; 62(2):720-9. PubMed ID: 12110039
    [No Abstract]   [Full Text] [Related]  

  • 60. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
    Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
    Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.